((自动化翻译由路透提供，请见免责声明 ))
9月26日 - ** Agios Pharmaceuticals 股价上涨~3%，报50.29美元；Fulcrum Therapeutics 上涨~20%，报4.15美元
** 较大的竞争对手辉瑞 从所有获批市场撤出其镰状细胞病药物Oxbryta， (link)，理由是该药物有引发痛苦的并发症和死亡的风险。
** 镰状细胞病是一种遗传性血液疾病，会影响红细胞中的血红蛋白
** 分析师预计，该药的退出将有助于促进竞争对手镰状细胞病药物（如 Agios 的 mitapivat 和 Fulcrum 的 pociredir）的试验注册。
** Piper Sandler 分析师认为："我们预计这将增加对 mitapivat 临床开发的关注和紧迫性。
** Leerink Partners的分析师称，Oxbryta的退出可能会对FULC早期研究的入组产生积极影响，尤其是正在或曾经单独服用Oxbryta的患者。
** 包括本交易日的涨幅在内，AGIO的股价上涨了一倍多，而FULC的股价则在本交易日下跌。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.